司美格鲁肽(胰高血糖素样肽-1受体激动剂)治疗开始后基于CT的体成分在同一个体内的变化
回顾性研究纳入241例接受司美格鲁肽治疗的成人,应用自动化CT人工智能体成分工具比较用药前后扫描。减重≥5 kg组(n=67)内脏脂肪面积、皮下脂肪面积、肌肉面积及肝脏体积降低,肝衰减升高;增重≥5 kg组(n=48)内脏脂肪、皮下脂肪及肌间脂肪面积增加,肌肉衰减降低。
要点
- 司美格鲁肽减重患者CT体成分呈心脏代谢风险相关的总体有利变化。
- 增重患者内脏脂肪、皮下脂肪及肌间脂肪面积增加,肌肉衰减降低提示肌肉质量下降。
- 自动化CT人工智能工具可提供超出常规临床指标的体成分变化生物标志物。
核心结论
- 使用司美格鲁肽的患者中,减重者与增重者呈现不同的CT体成分变化模式;减重者心脏代谢风险相关指标总体有利,增重者肌肉衰减降低与肌肉质量下降一致。
研究设计与样本
- 回顾性研究纳入241例接受司美格鲁肽治疗的成人(151例女性、90例男性,平均年龄60.4±12.4岁),于2016年1月至2023年11月间在司美格鲁肽开始前5年内及开始后5年内均接受腹盆腔CT。
关键影像表现/征象
- 减重组(n=67)用药后较用药前内脏脂肪面积降低(309.4 vs 341.1 cm2,p < .001)。
- 减重组用药后皮下脂肪面积降低(371.4 vs 410.7 cm2,p < .001),肌肉面积降低(179.2 vs 193.0,p < .001)。
- 减重组用药后肝脏体积降低(2379.0 vs 2578 HU,p = .009),肝衰减升高(74.5 vs 67.6 HU,p = .03)。
- 增重组(n=48)用药后内脏脂肪面积增加(334.0 vs 312.8,p = .002),皮下脂肪面积增加(485.8 vs 448.8 cm2,p = .01)。
- 增重组用药后肌间脂肪面积增加(48.4 vs 37.6,p = .009),肌肉衰减降低(5.9 vs 13.1,p < .001)。
诊断标准与关键数值
- 减重组定义为两次扫描间体重下降≥5 kg(n=67),增重组定义为体重增加≥5 kg(n=48)。
- 自动化CT人工智能体成分工具量化内脏脂肪面积、皮下脂肪面积、骨骼肌面积与衰减、肌间脂肪面积、肝脏体积与衰减及骨小梁骨密度。
临床应用与阅片要点
- 使用司美格鲁肽的患者中,自动化CT人工智能体成分工具可提供常规临床指标之外的体成分变化生物标志物。
- 减重者内脏脂肪面积、皮下脂肪面积、肌肉面积及肝脏体积降低,肝衰减升高,与心脏代谢风险相关的总体有利变化一致。
- 增重者内脏脂肪面积、皮下脂肪面积及肌间脂肪面积增加,肌肉衰减降低,与肌肉质量下降一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. The long-acting glucagon-like peptide-1 receptor agonist semaglutide is used to treat type 2 diabetes or obesity in adults. Clinical trials have observed associations of semaglutide with weight loss, improved control of diabetes, and cardiovascular risk reduction. OBJECTIVE. The purpose of this study was to evaluate intrapatient changes in body composition after initiation of semaglutide therapy by applying an automated suite of CT-based artificial intelligence (AI) body composition tools. METHODS. This retrospective study included adult patients who were receiving semaglutide treatment and who, between January 2016 and November 2023, underwent abdominopelvic CT within both 5 years before and 5 years after initiation of semaglutide. An automated suite of previously validated CT-based AI body composition tools was applied to scans obtained before semaglutide initiation (hereafter, presemaglutide scans) and scans obtained after semaglutide initiation (hereafter, postsemaglutide scans) to quantify visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) area, skeletal muscle area and attenuation, intermuscular adipose tissue (IMAT) area, liver volume and attenuation, and trabecular bone mineral density (BMD). Patients with weight loss of 5 kg or more and those with weight gain of 5 kg or more between the scans were compared. RESULTS. The study included 241 patients (151 women and 90 men; mean age, 60.4 ± 12.4 [SD] years). In the weight-loss group (n = 67), the postsemaglutide scan, compared with the presemaglutide scan, showed a decrease in VAT area (309.4 vs 341.1 cm2, p < .001), SAT area (371.4 vs 410.7 cm2, p < .001), muscle area (179.2 vs 193.0, p < .001), and liver volume (2379.0 vs 2578 HU, p = .009) and an increase in liver attenuation (74.5 vs 67.6 HU, p = .03). In the weight-gain group (n = 48), the postsemaglutide scan, compared with the presemaglutide scan, showed an increase in VAT area (334.0 vs 312.8, p = .002), SAT area (485.8 vs 448.8 cm2, p = .01), and IMAT area (48.4 vs 37.6, p = .009) and a decrease in muscle attenuation (5.9 vs 13.1, p < .001). Other comparisons were not statistically significant (p > .05). CONCLUSION. Patients using semaglutide who lost versus gained weight showed distinct patterns of changes in CT-based body composition measures. Those with weight loss had overall favorable shifts in measures related to cardiometabolic risk. A decrease in muscle attenuation in those with weight gain is consistent with decreased muscle quality. CLINICAL IMPACT. Among patients using semaglutide, automated CT-based AI tools provide biomarkers of changes in body composition beyond those that are evident by standard clinical measures.
引用
- Nelson LW, Lee MH, Garrett JW, et al. Intrapatient Changes in CT-Based Body Composition After Initiation of Semaglutide (Glucagon-Like Peptide-1 Receptor Agonist) Therapy. AJR Am J Roentgenol. 2024. PMID: 39230989. doi:10.2214/AJR.24.31805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。